Señalización PI3K / Akt / mTOR
Los inhibidores de la señalización PI3K/Akt/mTOR son compuestos que se dirigen a las vías de la fosfoinositida 3-cinasa (PI3K), la cinasa Akt y el blanco de la rapamicina en mamíferos (mTOR). Estas vías son reguladores críticos del crecimiento celular, la supervivencia, el metabolismo y la autofagia, lo que las convierte en objetivos clave en la investigación del cáncer y los trastornos metabólicos. Inhibir estas vías puede ayudar a controlar el crecimiento y la proliferación tumoral, ofreciendo potenciales estrategias terapéuticas para varios tipos de cáncer y otras enfermedades caracterizadas por una señalización celular desregulada. En CymitQuimica, ofrecemos una amplia selección de inhibidores de alta calidad de PI3K/Akt/mTOR para apoyar su investigación en oncología, señalización celular y enfermedades metabólicas.
Subcategorías de "Señalización PI3K / Akt / mTOR"
- AMPK(158 productos)
- ATM / ATR(71 productos)
- ADN-PK(51 productos)
- EGFR(572 productos)
- MELK(7 productos)
- PDK(9 productos)
- PI3K(242 productos)
- Quinasa S6(9 productos)
- gsk-3(112 productos)
- mTOR(144 productos)
Mostrar 2 subcategorías más
Se han encontrado 1038 productos de "Señalización PI3K / Akt / mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Duvelisib
CAS:<p>Duvelisib (INK1197, IPI-145) is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) and p100δ.Cost-effective and quality-assured.</p>Fórmula:C22H17ClN6OPureza:98.87% - 99.74%Forma y color:SolidPeso molecular:416.86PIK-75
CAS:<p>PIK-75, a DNA-PK and PI3K inhibitor, suppresses DNA-PK(IC50=2 nM), p110α(IC50=5.8 nM) and p110γ(IC50=76 nM).</p>Fórmula:C16H14BrN5O4SPureza:98.52% - >99.99%Forma y color:SolidPeso molecular:452.28PD153035
CAS:<p>PD153035 (NSC-669364) hydrochloride is an effective and selective inhibitor of EGFR (Ki/IC50: 5.2/29 pM, in cell-free assays); little inhibitory against FGFR,</p>Fórmula:C16H14BrN3O2Pureza:98.47% - 99.29%Forma y color:SolidPeso molecular:360.21Acalisib
CAS:<p>Acalisib (CAL-120) (GS-9820) is a potent and selective inhibitor of PI3Kδ.</p>Fórmula:C21H16FN7OPureza:98.99% - ≥95%Forma y color:SolidPeso molecular:401.4Nazartinib
CAS:<p>Nazartinib (EGF816) (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (</p>Fórmula:C26H31ClN6O2Pureza:98.63% - ≥95%Forma y color:Solid PowderPeso molecular:495.02Vacuolin-1
CAS:<p>Vacuolin-1 is a cell-permeable inhibitor of Ca2+ dependent fusion of lysosomes to the cell membrane.</p>Fórmula:C26H24IN7OPureza:97.20% - 98.45%Forma y color:SolidPeso molecular:577.42HG-9-91-01
CAS:<p>HG-9-91-01 (SIK inhibitor 1) is a potent and highly selective salt-inducible kinase (SIKs) inhibitor with IC50s of 0.92 nM, 6.6 nM and 9.6 nM for SIK1, SIK2 and</p>Fórmula:C32H37N7O3Pureza:96.86% - 99.71%Forma y color:SolidPeso molecular:567.68CZC24832
CAS:<p>CZC24832 is a selective inhibitor of PI 3-kinase γ.</p>Fórmula:C15H17FN6O2SPureza:99.08% - 99.12%Forma y color:SolidPeso molecular:364.4PD-089828
CAS:<p>PD 089828 inhibits FGFR1, PDGFRβ, EGFR (IC50s: 0.15-5.47 μM), and c-Src (IC50: 0.18 μM).</p>Fórmula:C18H18Cl2N6OPureza:97.39%Forma y color:SolidPeso molecular:405.28Parsaclisib hydrochloride
CAS:<p>Parsaclisib hydrochloride (INCB050465 HCl) is a selectve PI3Kδ inhibitor with antitumor activity. Parsaclisib demonstrates potent activity.</p>Fórmula:C20H23Cl2FN6O2Pureza:98%Forma y color:SolidPeso molecular:469.34COH-SR4
CAS:<p>COH-SR4 (COH-SR4 (Mitochondria uncoupler SR4)) is a uncoupler of mitochondrial oxidative phosphorylation.</p>Fórmula:C13H8Cl4N2OPureza:98.96%Forma y color:SolidPeso molecular:350.03RLY-2608
CAS:<p>RLY-2608 is a variant PI3Kalpha inhibitor that inhibits tumor growth in a PIK3CA mutant xenograft model.</p>Fórmula:C29H14ClF5N6O2Pureza:98.62% - 98.7%Forma y color:SolidPeso molecular:608.91740 Y-P
CAS:<p>740 Y-P (740YPDGFR) is a PI3K activator with cell permeability,binds GST fusion proteins containing the N-and C-terminal SH2 domains of p85. Low-Cost!</p>Fórmula:C141H222N43O39PS3Pureza:98.3% - 99.87%Forma y color:SolidPeso molecular:3270.7Gefitinib hydrochloride
CAS:<p>Obtustatin triacetate is an integrin derived from the venom of Vipera lebetina obtusa and is an α1β1 integrin and in vivo angiogenesis inhibitor.</p>Fórmula:C22H25Cl2FN4O3Pureza:99.8%Forma y color:SolidPeso molecular:483.36CHIR 98024
CAS:<p>CHIR 98024: strong GSK-3α/β blocker, IC50 0.65/0.58 nM, selective over Cdc2/ERK2.</p>Fórmula:C20H17Cl2N9O2Pureza:96.74%Forma y color:SolidPeso molecular:486.31Cavutilide
CAS:<p>Cavutilide has antiarrhythmic activity, inhibits hERG K(+) channels, and can be used to study heart failure and persistent atrial fibrillation.</p>Fórmula:C22H26FN3O3Pureza:99.82% - 99.85%Forma y color:SolidPeso molecular:399.458BMS-690514
CAS:<p>BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR. It has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.</p>Fórmula:C19H24N6O2Pureza:99.08%Forma y color:SolidPeso molecular:368.43Naquotinib mesylate
CAS:<p>Naquotinib mesylate (ASP8273 (mesylate)) is an orally available, mutant-selective and irreversible inhibitor of EGFR(iC50s of 8-33 nM and 230 nM for toward EGFR</p>Fórmula:C31H46N8O6SPureza:98%Forma y color:SolidPeso molecular:658.81Canertinib dihydrochloride
CAS:<p>Canertinib dihydrochloride (PD-183805 dihydrochloride) is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and</p>Fórmula:C24H27Cl3FN5O3Pureza:99.13% - >99.99%Forma y color:SolidPeso molecular:558.86Almonertinib hydrochloride
CAS:<p>Almonertinib hydrochloride (HS-10296 hydrochloride) is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation.</p>Fórmula:C30H36ClN7O2Pureza:98.01% - 98.12%Forma y color:SolidPeso molecular:562.1Imgatuzumab
CAS:<p>Imgatuzumab (RG 7160) is a humanized anti-EGFR monoclonal antibody and immunomodulator for cancer research.</p>Forma y color:LiquidPeso molecular:145.0 (kDa)Depatuxizumab
CAS:<p>Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, inhibit tumor growth,GBM,SCCHN.</p>Pureza:95%Forma y color:LiquidElgemtumab
CAS:<p>Elgemtumab (LJM716) is a fully humanised monoclonal antibody targeting HER3/ERBB3, acting as an antagonist to block HER3/Akt phosphorylation antitumour.</p>Pureza:95%Forma y color:LiquidZalutumumab
CAS:<p>Zalutumumab is a high-affinity fully human monoclonal antibody ,the extracellular domain of the EGFR squamous cell carcinoma of the head and neck (SCCHN).</p>Pureza:95%Forma y color:LiquidIzalontamab
CAS:<p>Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR×EGFR homodimers and EGFR×HER3 heterodimers.</p>Pureza:95%+ - 95%+Forma y color:LiquidBecotatug
CAS:<p>Becotatug (JMT-101) is an IgG1 antibody that targets EGFR and can be conjugated to Afatinib and Osimertinib, functioning as a synthetic antibody-drug conjugate</p>Pureza:95% - 95%Forma y color:LiquidAnbenitamab
CAS:<p>Anbenitamab (KN-026) is a bispecific HER2 antibody for metastatic breast cancer research, blocking HER2 pathways and mediating ADCC.</p>Forma y color:LiquidPonezumab
CAS:<p>Ponezumab (PF-04360365), a humanized IgG2 antibody, lowers Aβ in the CNS & boosts mice memory. Used in Alzheimer's research.</p>Forma y color:LiquidFutuximab
CAS:<p>Futuximab, a chimeric monoclonal antibody, targets distinct epitopes on the epidermal growth factor receptor (EGFR), exhibiting antineoplastic activity [1].</p>Pureza:95% - 95%Forma y color:LiquidZanidatamab
CAS:<p>Zanidatamab (ZW25) is a bispecific, humanized monoclonal antibody that targets two distinct epitopes (ECD2 and ECD4) of the HER2 receptor, exhibiting anti-tumor</p>Forma y color:LiquidSerclutamab
CAS:<p>Serclutamab, a humanized chimeric monoclonal antibody of the IgG1-κ isotype, selectively targets the epidermal growth factor receptor (EGFR).</p>Pureza:98%Forma y color:Liquid1-Azakenpaullone
CAS:<p>1-Azakenpaullone (azakenpaullone) is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25.</p>Fórmula:C15H10BrN3OPureza:99.73%Forma y color:Tan SolidPeso molecular:328.16Icotinib
CAS:<p>Icotinib (Conmana) is an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity.</p>Fórmula:C22H21N3O4Pureza:99.76% - 99.94%Forma y color:SolidPeso molecular:391.42IGF-1R modulator 1
CAS:<p>IGF-1Rmodulator 1 (Example 5) is an IGF-1R modulator featuring an EC50 of 0.29 μM (FGFR1), 0.25 μM (IGF1R), 0.34 μM (TrkA), and 0.39 μM (TrkB). This compound is useful in research on diseases characterized by impaired signaling of neurotrophic and/or other trophic factors, such as Alzheimer's disease.</p>Fórmula:C22H17N3O4Forma y color:SolidPeso molecular:387.39lavendustin A
CAS:<p>lavendustin A (RG-14355) is a potent, cell-permeable inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.</p>Fórmula:C21H19NO6Pureza:98%Forma y color:Off-White SolidPeso molecular:381.38GSK2292767
CAS:<p>GSK2292767 is a potent and selective PI3Kδ inhibitor.</p>Fórmula:C24H28N6O5SPureza:98%Forma y color:SolidPeso molecular:512.58ZM323881 hydrochloride
CAS:<p>ZM323881 hydrochloride (ZM 323881 HCl) is a potent and selective VEGFR2 inhibitor.</p>Fórmula:C22H19ClFN3O2Pureza:99.43%Forma y color:SolidPeso molecular:411.86CNX-1351
CAS:<p>CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor.</p>Fórmula:C30H35N7O3SPureza:99.66% - 99.83%Forma y color:SolidPeso molecular:573.71Icotinib Hydrochloride
CAS:<p>Icotinib Hydrochloride, an oral EGFR inhibitor (BPI-2009H), may halt cancer growth by blocking EGFR signaling.</p>Fórmula:C22H22ClN3O4Pureza:99.89%Forma y color:SolidPeso molecular:427.88TAK-285
CAS:<p>TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.</p>Fórmula:C26H25ClF3N5O3Pureza:99.73%Forma y color:SolidPeso molecular:547.96CAL-130
CAS:<p>CAL-130 is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).</p>Fórmula:C23H22N8OPureza:98%Forma y color:SolidPeso molecular:426.47TCS 2002
CAS:<p>GSK-3β inhibitor 9b: potent, selective, oral, IC50=35 nM, good pharmacokinetics, BBB-permeable, researched for Alzheimer's.</p>Fórmula:C18H14N2O3SForma y color:SolidPeso molecular:338.38MS 154N
CAS:<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Fórmula:C47H56ClFN8O8Forma y color:SolidPeso molecular:915.45PI3K/mTOR Inhibitor-9
CAS:<p>PI3K/mTOR Inhibitor-9 acts on mTOR (38 nM IC50) and PI3Kα/γ (6.6 nM IC50), PI3Kδ (0.8 nM IC50).</p>Fórmula:C23H27N7O2Forma y color:SolidPeso molecular:433.51EGFR-IN-16
CAS:<p>EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.</p>Fórmula:C16H11NO3Pureza:98%Forma y color:SolidPeso molecular:265.26NVP-CLR457
CAS:<p>NVP-CLR457 is an oral pan-class I PI3K inhibitor with dose-dependent antitumor activity.</p>Fórmula:C18H20F3N7O4Forma y color:SolidPeso molecular:455.39NU-7163
CAS:<p>NU-7163 is a potent and selective inhibitor of ATP-competitive DNA-PK.</p>Fórmula:C18H17NO3Pureza:98%Forma y color:SolidPeso molecular:295.33EGA
CAS:<p>EGA blocks the entry of a variety of other acid-dependent bacterial toxins and viruses into mammalian cells and can be used to treat infectious diseases.</p>Fórmula:C16H16BrN3OPureza:98% - 99.6%Forma y color:SolidPeso molecular:346.22EGFR-IN-67
CAS:<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Fórmula:C18H17N3SForma y color:SolidPeso molecular:307.41DS21360717
CAS:<p>DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.</p>Fórmula:C21H23N7OPureza:98%Forma y color:SolidPeso molecular:389.45DNA-PK-IN-1
CAS:<p>DNA-PK-IN-1 is a potent inhibitor of DNA-PK. DNA-PK-IN-1 has potential for cancer disease research.</p>Fórmula:C23H26N8O2Forma y color:SolidPeso molecular:446.5WR23
CAS:<p>WR23 is a piperidinylquinoxaline derivative and a phosphoinositide 3-kinase α (PI3Kα) inhibitor.</p>Fórmula:C19H18BrN3O3SPureza:98%Forma y color:SolidPeso molecular:448.33LTURM-36
CAS:<p>LTURM-36 is a novel inhibitor of PI 3-kinase delta.</p>Fórmula:C22H18N2O3Pureza:98%Forma y color:SolidPeso molecular:358.39ZDWX-25
CAS:<p>ZDWX-25, a strong GSK-3β & DYRK1A inhibitor, kills SH-SY5Y/HL-7702 cells, may aid Alzheimer's research; IC50: 71 nM for GSK-3β.</p>Fórmula:C17H15N3O3Forma y color:SolidPeso molecular:309.32MIPS-9922
CAS:<p>MIPS-9922: potent PI3Kβ inhibitor; prevents αIIbβ3 activation, platelet adhesion, and ADP-triggered aggregation.</p>Fórmula:C28H31F2N9O2Pureza:98%Forma y color:SolidPeso molecular:563.6NSC81111
CAS:<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Fórmula:C19H16O4Forma y color:SolidPeso molecular:308.33Limertinib
CAS:<p>Limertinib (ASK120067) is a EGFR tyrosine kinase inhibitor targeting EGFR T790M, applicable for the study of non-small cell lung cancer.</p>Fórmula:C29H32ClN7O2Pureza:97.44%Forma y color:SolidPeso molecular:546.06GNE-293
CAS:<p>GNE-293 is a potent and selective PI3Kδ inhibitor.</p>Fórmula:C28H36N8O4SPureza:98%Forma y color:SolidPeso molecular:580.7PI-540
CAS:<p>PI-540 is a potent and selective inhibitor of class 1A phosphatidylinositide 3-kinases (PI3K).</p>Fórmula:C22H27N5O2SForma y color:SolidPeso molecular:425.55DNA-PK-IN-3
CAS:<p>DNA-PK-IN-3 is a potent DNA-PK inhibitor, enhancing radio/chemotherapy and reducing tumors with limited side effects.</p>Fórmula:C19H19N9OForma y color:SolidPeso molecular:389.41PI3K-IN-6
CAS:<p>PI3K-IN-6 is an oral active and highly selective inhibitor of phosphoinositide 3-kinase (PI3K) β/δ(IC50 values of 7.8 nM/5.3 nM , respectively).</p>Fórmula:C17H14Cl2FN9OPureza:98%Forma y color:SolidPeso molecular:450.26PI3Kδ/γ-IN-2
CAS:<p>PI3Kδ/γ-IN-2 is a potent, orally bioavailable dual inhibitor of PI3Kδ (IC50: 1 nM) and PI3Kγ (IC50: 4.3 nM) with potential for use in anti-B-cell malignancy</p>Fórmula:C25H21ClN8OForma y color:SolidPeso molecular:484.94GLPG3970
CAS:<p>GLPG3970, a pioneering inhibitor of SIK2/SIK3, is utilized in the investigation of inflammation and autoimmune diseases.</p>Fórmula:C25H27F3N4O4Pureza:99.60% - >99.99%Forma y color:SolidPeso molecular:504.5EGFR-IN-68
CAS:<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Fórmula:C24H22N2OForma y color:SolidPeso molecular:354.44EAI001
CAS:<p>EAI001 is a potent and selective mutant epidermal growth factor receptor (EGFR) variant inhibitor that inhibits EGFRL858R/T790M with an IC50 value of 24 nM.</p>Fórmula:C19H15N3O2SPureza:>99.99%Forma y color:SolidPeso molecular:349.41PI3Kγ inhibitor 4
CAS:<p>PI3Kγ inhibitor 4 is a selective, potent, orally active PI3Kγ inhibitor (IC50: 40 nM).</p>Fórmula:C20H24N4O4SForma y color:SolidPeso molecular:416.49Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Pureza:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Forma y color:LiquidMRT80
CAS:<p>MRT80 is an inhibitor of GSK-3 in vitro. MRT80 de-stabilizes MDM2 and stabilizes p53 protein and E2F-1.</p>Fórmula:C15H15N5OPureza:98%Forma y color:SolidPeso molecular:281.31mTOR inhibitor-2
CAS:<p>mTOR inhibitor-2 is an inhibitor of selective and oral mTOR (IC50 of 7 nM).</p>Fórmula:C23H21N7OPureza:98%Forma y color:SolidPeso molecular:411.46SDZ281-977
CAS:<p>SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.</p>Fórmula:C18H20O5Pureza:99.64%Forma y color:SolidPeso molecular:316.35(E/Z)-CP-724714
CAS:<p>(E/Z)-CP-724714, comprising racemic mixtures of (E)-CP-724714 and (Z)-CP-724714 isomers, is a potent, selective, and orally active inhibitor of ErbB2 (HER2)[1].</p>Fórmula:C27H27N5O3Pureza:98%Forma y color:SolidPeso molecular:469.54AG-183
CAS:<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Fórmula:C13H8N4O3Forma y color:Brown SolidPeso molecular:268.23PI3Kα-IN-13
CAS:<p>PI3Kα-IN-13 (Compound 18a), a PI3Kα inhibitor with an IC50 of 2.5 nM, effectively induces apoptosis and hampers the proliferation of various cancer cell lines,</p>Fórmula:C21H19N5O3Pureza:98%Forma y color:SolidPeso molecular:389.41Nemiralisib
CAS:<p>Nemiralisib (GSK-2269557) is an oral PI3Kδ inhibitor (pKi 9.9) for treating respiratory diseases like COPD.</p>Fórmula:C26H28N6OPureza:99.91%Forma y color:SolidPeso molecular:440.54PI4KIII β inhibitor 3
CAS:<p>PI4KIII beta inhibitor 3 is a novel and high effective inhibitor of PI4KIIIβ (IC50 of 5.7 nM).</p>Fórmula:C22H22N8OSPureza:98%Forma y color:SolidPeso molecular:446.53TGX-155
CAS:<p>TGX-155 is a selective PI3K inhibitor.</p>Fórmula:C20H19FN2O3Pureza:98%Forma y color:SolidPeso molecular:354.37FT-1518
CAS:<p>FT-1518 is an orally available, selective and potent mTORC1 and mTORC2 inhibitor with anticancer and antitumor activity for cancer research.</p>Fórmula:C20H26N8OPureza:98.34% - 98.80%Forma y color:SolidPeso molecular:394.47Tarlox-TKI
CAS:<p>Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.</p>Fórmula:C19H18BrClN6OPureza:97.03%Forma y color:SolidPeso molecular:461.74AZD3458
CAS:<p>AZD3458 is a potent and remarkably selective inhibitor of PI3Kγ (PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ with pIC50s of 9.1, 5.1, <4.5, and 6.5 , respectively).</p>Fórmula:C20H23N3O4S2Forma y color:SolidPeso molecular:433.54RV-1729
CAS:<p>RV-1729, a phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor, is used potentially for the treatment of asthma.</p>Fórmula:C39H39ClN8O5Forma y color:SolidPeso molecular:735.23BKI-1369
CAS:<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Fórmula:C23H27N7OForma y color:SolidPeso molecular:417.51RTC-5
CAS:<p>RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.</p>Fórmula:C24H22ClF3N2O3SPureza:98.14%Forma y color:SolidPeso molecular:510.96CAL-130 Hydrochloride
CAS:<p>CAL-130 Hydrochloride is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).</p>Fórmula:C23H23ClN8OForma y color:SolidPeso molecular:462.94EGFR-IN-50
CAS:<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Fórmula:C24H26BrN3O4S2Forma y color:SolidPeso molecular:564.51NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C22H20O4Forma y color:SolidPeso molecular:348.39JBJ-04-125-02
CAS:<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Fórmula:C29H26FN5O3SPureza:98%Forma y color:SolidPeso molecular:543.61PIKfyve-IN-2
CAS:<p>PIKfyve-IN-2 is a potent inhibitor of the PIKfyve kinase, with potential applications in cancer and autoimmune disorder research [1].</p>Fórmula:C22H22N8OForma y color:SolidPeso molecular:414.46BRD3731
CAS:<p>BRD3731 selectively inhibits GSK3β with IC50 of 15 nM; it's promising for PTSD, psychiatric issues, diabetes, and neurodegeneration.</p>Fórmula:C24H31N3OForma y color:SolidPeso molecular:377.523F8
CAS:<p>3F8 is a selective GSK-3β inhibitor that can be used as a new tool and potential therapeutic candidate compound for GSK3-related diseases, and can be used in</p>Fórmula:C15H14N2O4Pureza:98.14% - 98.25%Forma y color:SolidPeso molecular:286.28Epertinib
CAS:<p>Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).</p>Fórmula:C30H27ClFN5O3Pureza:98%Forma y color:SolidPeso molecular:560.02EGFR-IN-64
CAS:<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Fórmula:C20H21N3O3Forma y color:SolidPeso molecular:351.4(R)-PS210
CAS:<p>(R)-PS210, the R enantiomer of PS210 is a substrate-selective allosteric PDK1 activator with an (AC50 of 1.8 μM).</p>Fórmula:C19H15F3O5Forma y color:SolidPeso molecular:380.31GW 583340 dihydrochloride
CAS:<p>GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 inhibitor and inhibits 80% of tumor growth in a mouse xenograft mode.</p>Fórmula:C28H27Cl3FN5O3S2Pureza:98.80%Forma y color:SolidPeso molecular:671.03FD2056
CAS:<p>FD2056 is a potent, orally active PI3K inhibitor, with IC50 values of 0.30, 0.80, 1.10, and 0.42 nM against PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively.</p>Fórmula:C23H17ClN6O2SPureza:98%Forma y color:SolidPeso molecular:476.94EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Fórmula:C26H31FN8O2SPureza:98%Forma y color:SolidPeso molecular:538.64AMPK activator 12
CAS:<p>AMPK activator 12 is an AMPK activator and GDF15 inducer that elevates the expression level of GDF15 protein for cancer research.</p>Fórmula:C23H24BrNO2Pureza:99.55%Forma y color:SolidPeso molecular:426.35PI5P4Ks-IN-1
CAS:<p>PI5P4Ks-IN-1 (compound 7) is an active compound which engages PI5P4Kγ[1].</p>Fórmula:C20H17N3SForma y color:SolidPeso molecular:331.43Antiproliferative agent-34
CAS:<p>Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT.</p>Fórmula:C27H27N7O5Pureza:98%Forma y color:SolidPeso molecular:529.55PIMPC
CAS:<p>PIMPC, a compound endowed with antioxidant and metal-chelating properties, acts as a novel inhibitor of glycogen synthase kinase 3 (GSK-3), and exhibits</p>Fórmula:C21H19N5OPureza:98%Forma y color:SolidPeso molecular:357.41PI3Kγ inhibitor 7
CAS:<p>PI3Kγ Inhibitor 7 (compound 2) is a potent, orally active agent that selectively inhibits PI3Kγ with an IC50 of 3.42 nM and demonstrates antitumor activity [1].</p>Fórmula:C31H25N9O2Pureza:98%Forma y color:SolidPeso molecular:555.59EGFR-IN-73
CAS:<p>EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1].</p>Fórmula:C19H17ClFN3O4Pureza:98%Forma y color:SolidPeso molecular:405.81Selatinib
CAS:<p>Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.</p>Fórmula:C29H26ClFN4O3SPureza:98.00%Forma y color:SolidPeso molecular:565.06CGP52411
CAS:<p>CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM).</p>Fórmula:C20H15N3O2Pureza:99.78%Forma y color:SolidPeso molecular:329.35PI3K/mTOR Inhibitor-4
CAS:<p>Oral PI3K/mTOR Inhibitor-4 targets PI3Kα, γ, δ, mTOR; IC50s: 0.63, 22, 9.2, 13.85 nM. Used in cancer research.</p>Fórmula:C27H22FN3O6SForma y color:SolidPeso molecular:535.54BRD0209
CAS:<p>BRD0209 is a highly selective and potent GSK3 inhibitor.</p>Fórmula:C22H25N3OPureza:99.92%Forma y color:SolidPeso molecular:347.45GSK-3β inhibitor 12
CAS:<p>GSK-3β inhibitor 12 is a selective GSK-3β inhibitor.GSK-3β inhibitor 12 inhibits 49.11% of 25 μM GSK-3β activity and 37.11% of 50 μM GSK-3β activity.GSK-3β</p>Fórmula:C14H13N3OSPureza:98.58%Forma y color:SolidPeso molecular:271.34NVS-PI3-4
CAS:<p>NVS-PI3-4: A selective PI3Kγ inhibitor for research in allergies, inflammation, and cancer.</p>Fórmula:C20H26N4O3SForma y color:SolidPeso molecular:402.51TC-G 24
CAS:<p>GSK-3β inhibitor</p>Fórmula:C15H11ClN4O3Pureza:98%Forma y color:SolidPeso molecular:330.73JNJ28871063 hydrochloride
CAS:<p>ErbB receptor family inhibitor</p>Fórmula:C24H28Cl2N6O3Pureza:98%Forma y color:SolidPeso molecular:519.42(S)-PI3Kα-IN-4
CAS:<p>(S)-PI3Kα-IN-4 is a potent inhibitor of PI3Kα, with an IC50 of 2.3 nM.</p>Fórmula:C25H23ClFN5O5SForma y color:SolidPeso molecular:56018BIOder
CAS:<p>18BIOder is a neuroprotective inhibitor of GSK-3β, highly selectively inhibiting HIV-1. It is the second generation derivative of 6BIO.</p>Fórmula:C9H7ClN2O2Pureza:98%Forma y color:SolidPeso molecular:210.62Tyrphostin 51
CAS:<p>Tyrphostin 51 is an effective inhibitor of EGFR kinase.</p>Fórmula:C13H8N4O3Pureza:98%Forma y color:SolidPeso molecular:268.23CHMFL-PI3KD-317
CAS:<p>CHMFL-PI3KD-317: potent PI3Kδ inhibitor, IC50=6 nM, orally active, >10x selective vs. PI3K isoforms, anti-cancer.</p>Fórmula:C21H24ClN5O3S2Pureza:99.16%Forma y color:SolidPeso molecular:494.03MS 39
CAS:<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Fórmula:C55H71ClFN9O7SForma y color:SolidPeso molecular:1056.72PI3KD/V-IN-01
CAS:<p>PI3KD/V-IN-01 is a potent ATP-competitive PI3Kδ/Vps34 dual inhibitor.</p>Fórmula:C21H24ClN5O3S2Pureza:98%Forma y color:SolidPeso molecular:494.03AZ2
CAS:<p>AZ2 is a highly selective, active PI3Kγ inhibitor (pIC50=9.3) for use in inflammatory and immune disorders.</p>Fórmula:C20H23N3O2SPureza:99.25%Forma y color:SolidPeso molecular:369.48Gefitinib N-oxide
CAS:<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Fórmula:C22H24ClFN4O4Pureza:98%Forma y color:SolidPeso molecular:462.9Cazpaullone
CAS:<p>Cazpaullone inhibits GSK-3 and briefly boosts Pax4 mRNA expression.</p>Fórmula:C16H10N4OForma y color:SolidPeso molecular:274.28DBPR112
CAS:<p>DBPR112: oral furanopyrimidine EGFR inhibitor; IC50: 15 nM (EGFRWT), 48 nM (L858R/T790M); blocks ATP site, strong antitumor effects.</p>Fórmula:C32H31N5O3Pureza:99.25%Forma y color:SolidPeso molecular:533.62AM-0687
CAS:<p>AM-0687: Strong PI3Kδ blocker; pAKT IC50=0.7nM, u(pAKT) IC50=4.6nM; Rat IgG ED50=0.026mg/kg, IgM ED50=0.016mg/kg; Clu=2.3L/hr/kg.</p>Fórmula:C23H19FN8OPureza:98%Forma y color:SolidPeso molecular:442.45VP3.15
CAS:<p>VP3.15 is an orally bioavailable and CNS-penetrant dual inhibitor of phosphodiesterase (PDE)7- GSK3 (IC50s: 1.59 μM and 0.88 μM for PDE7 and GSK-3).</p>Fórmula:C20H22N4OSPureza:98%Forma y color:SolidPeso molecular:366.48GSK3-IN-2
CAS:<p>GSK3-IN-2 is a potent GSK3 inhibitor for the treatment of diabetes and neurodegenerative diseases.</p>Fórmula:C17H19N3OSPureza:98.8%Forma y color:SolidPeso molecular:313.423,5-dimethyl PIT-1
CAS:<p>PtdIns-(3,4,5)-P3 (PIP3) serves as an anchor for the binding of signal transduction proteins bearing pleckstrin homology (PH) domains such as</p>Fórmula:C16H15N3O4SForma y color:SolidPeso molecular:345.37Aloisine B
CAS:<p>Aloisine B (AloisineB) inhibited cyclin-dependent kinase and glycogen synthase kinase with IC50 values of 0.85 µM and 0.75 µM, respectively.</p>Fórmula:C15H14ClN3Pureza:95.15%Forma y color:SolidPeso molecular:271.74PI3K/mTOR Inhibitor-2
CAS:<p>Potent PI3K/mTOR Inhibitor-2 targets PI3Kα/β/δ/γ & mTOR (IC50: 3.4, 34, 16,1, 4.7 nM); exhibits antitumor effects.</p>Fórmula:C20H13ClF2N4O4SPureza:96.16%Forma y color:SolidPeso molecular:478.86PI3Kdelta inhibitor 1
CAS:<p>PI3Kdelta inhibitor 1 is a potent, selective and orally available inhibitor of PI3Kδ with an IC50 of 1.3 nM.</p>Fórmula:C27H38N6O5SPureza:98%Forma y color:SolidPeso molecular:558.69Mutated EGFR-IN-3
CAS:<p>Mutated EGFR-IN-3: ATP-competitive, selective dibenzodiazepinone inhibitor for EGFR mutations, IC50 12-13 nM.</p>Fórmula:C31H29FN4O2Pureza:98%Forma y color:SolidPeso molecular:508.59Nazartinib mesylate
CAS:<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Fórmula:C27H35ClN6O5SPureza:98%Forma y color:SolidPeso molecular:591.12DNA-PK-IN-4
CAS:<p>DNA-PK-IN-4, an imidazolinone, targets DNA-PKcs to hinder tumor DNA repair and induce apoptosis, showing cancer research potential.</p>Fórmula:C20H24N6O3Forma y color:SolidPeso molecular:396.44EGFR/HER2-IN-9
CAS:<p>EGFR/HER2-IN-9, a compound inhibiting both EGFR and HER2, demonstrates potency with IC50 values of 3.2 nM for EGFR, 14 nM for HER2, and 8.3 nM against the EGFR</p>Fórmula:C25H25ClFN5O4Forma y color:SolidPeso molecular:513.95Lavendustin C6
CAS:<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Fórmula:C20H25NO5Forma y color:SolidPeso molecular:359.42Leniolisib phosphate
CAS:<p>Leniolisib phosphate is an effective PI3K inhibitor.</p>Fórmula:C21H28F3N6O6PForma y color:SolidPeso molecular:548.45BAY 2476568
CAS:<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Fórmula:C24H27FN4O4Forma y color:SolidPeso molecular:454.49EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Fórmula:C25H25Cl2N7O2Forma y color:SolidPeso molecular:526.42PKI-179
CAS:<p>PKI-179: Dual PI3K/mTOR inhibitor, orally active, IC50s: 0.42-77 nM, targets E545K and H1047R, antitumor in vivo.</p>Fórmula:C25H28N8O3Forma y color:SolidPeso molecular:488.54EGFR-IN-28
CAS:<p>EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .</p>Fórmula:C31H39BrN10O3SForma y color:SolidPeso molecular:711.68SIKs-IN-1
CAS:<p>SIKs-IN-1 (compound 8h), a pyrimidine-5-carboxamide derivative, functions as an inhibitor of Salt-inducible kinases (SIKs), which play a role in the M1/M2</p>Fórmula:C27H31F2N7OForma y color:SolidPeso molecular:507.58PI3K-IN-36
CAS:<p>PI3K-IN-36 is a potent inhibitor of PI3K, suitable for research applications in follicular lymphoma (FL).</p>Fórmula:C30H36F2N8OForma y color:SolidPeso molecular:562.66PI3Kγ inhibitor 6
CAS:<p>PI3Kγ Inhibitor 6, a specific inhibitor of PI3Kγ, is utilized in the study of inflammatory and autoimmune diseases.</p>Fórmula:C16H11NO5SForma y color:SolidPeso molecular:329.33PKI-179 hydrochloride
CAS:<p>PKI-179: oral PI3K/mTOR inhibitor; IC50: PI3Kα/β/δ/γ (8-74 nM), PI3Kα mutants (11-14 nM), mTOR (0.42 nM); selective; inhibits cancer cell growth.</p>Fórmula:C25H29ClN8O3Forma y color:SolidPeso molecular:525PI3K-IN-28
CAS:<p>PI3K-IN-28, a potent PI3K inhibitor with low toxicity in MCF-10a, has IC50 values of 5.8, 2.3, 7.9 μM and high selectivity index of 39.</p>Fórmula:C26H16F9N3O3S2Forma y color:SolidPeso molecular:653.54DNA-PK-IN-5
CAS:<p>DNA-PK-IN-5: potent DNA-PK inhibitor, reduces tumor repair, induces apoptosis, enhances radiotherapy, overcomes resistance.</p>Fórmula:C21H22N8O2Forma y color:SolidPeso molecular:418.45CAY10717
CAS:<p>CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.</p>Fórmula:C29H25F3N6O3Forma y color:SolidPeso molecular:562.54UNC-CA359
CAS:<p>UNC-CA359: potent EGFR inhibitor, IC50=18 nM, strong anti-tumor effect, promising for chordoma.</p>Fórmula:C18H14ClN3O2Forma y color:SolidPeso molecular:339.78EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Fórmula:C22H15N5O2SForma y color:SolidPeso molecular:413.45EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Fórmula:C10H6N6S2Forma y color:SolidPeso molecular:274.32PI3Kα-IN-4
CAS:<p>PI3Kα-IN-4 is a potent, selective, and orally active PI3Kα inhibitor, demonstrating an IC50 of 1.8 nM and exhibiting antitumor activity[1].</p>Fórmula:C25H23ClFN5O5SForma y color:SolidPeso molecular:560(E/Z)-AG490
CAS:<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Fórmula:C17H14N2O3Forma y color:SolidPeso molecular:294.3PI3K-IN-2
CAS:<p>PI3K-IN-2 inhibits PI3Kβ/δ (IC50: 7.1, 8.6 nM) with greater selectivity over PI3Kσ/γ (IC50: 13, 190 nM) and is orally active.</p>Fórmula:C28H29F2N3O5Forma y color:SolidPeso molecular:525.54PD 173955-Analog1
CAS:<p>PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.</p>Fórmula:C21H14Cl2N4O3Forma y color:SolidPeso molecular:441.27NVP-BBD130
CAS:<p>NVP-BBD130 is a stable, ATP-competitive, potent, orally active inhibitor of PI3K and mTOR.</p>Fórmula:C28H21N5OForma y color:SolidPeso molecular:443.5EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Fórmula:C26H23N5O3Forma y color:SolidPeso molecular:453.49DNA-PK-IN-7
CAS:<p>DNA-PK-IN-7 is a potent DNA-PK inhibitor (IC50= 1 nM) (WO2021104277A1, compound 5).</p>Fórmula:C19H21N9O2Forma y color:SolidPeso molecular:407.43eCF-309
CAS:<p>eCF-309 is a potent mTOR inhibitor with IC50 value of 15 nM.</p>Fórmula:C18H21N7O3Forma y color:SolidPeso molecular:383.4EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Fórmula:C32H36FN7O2Forma y color:SolidPeso molecular:569.67PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Fórmula:C28H26N8O4Forma y color:SolidPeso molecular:538.56BIBX 1382 Dihydrochloride
CAS:<p>BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.</p>Fórmula:C18H21Cl3FN7Forma y color:SolidPeso molecular:460.76LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Fórmula:C32H35N5O3Forma y color:SolidPeso molecular:537.65EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Fórmula:C31H37Cl2N7O3SForma y color:SolidPeso molecular:658.64PfGSK3/PfPK6-IN-2
CAS:<p>PfGSK3/PfPK6-IN-2 inhibits Plasmodium falciparum GSK3/PK6 (IC50: 172 nM/11 nM) for Malaria research.</p>Fórmula:C24H25Cl2N5OSForma y color:SolidPeso molecular:502.46EGFR-IN-63
CAS:<p>EGFR- IN-63 is an EGFR inhibitor with an IC50 value of 0.096 μM. EGFR- IN-63 exhibited anticancer effects on MCF-7 cells (IC50: 2.49 μM).</p>Fórmula:C20H12BrN5SForma y color:SolidPeso molecular:434.31PI3Kδ-IN-3
CAS:<p>PI3Kδ-IN-3 (TC KHNS 11) is a PI3Kδ inhibitor with an IC50 value of 9 nM.PI3Kδ-IN-3 has a favorable pharmacokinetic profile and inhibits B cell function.</p>Fórmula:C28H24N6O3Pureza:98.43%Forma y color:SolidPeso molecular:492.53EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4OXA-01
CAS:<p>OXA-01 is a potent mTORC1 and mTORC2 inhibitor, with IC 50 values of 29 nM and 7 nM, respectively [1]. OXA-01 demonstrates broad anti-tumor activity.</p>Fórmula:C21H20ClN5O2Forma y color:SolidPeso molecular:409.87BRD1652
CAS:<p>BRD1652 is a highly selective and potent GSK3 inhibitor.</p>Fórmula:C20H20F3N3OPureza:98%Forma y color:SolidPeso molecular:375.39CC260
CAS:<p>CC260 selectively inhibits PI5P4Kα/β (Ki: 40/30 nM), with minimal effect on Plk1/RSK2, useful for metabolic, diabetes, and cancer studies.</p>Fórmula:C24H29Cl2N5O2Forma y color:SolidPeso molecular:490.43AS2541019
CAS:<p>AS2541019 is a selective Phosphatidylinositol-3-kinase p110δ (PI3Kδ) inhibitor.</p>Fórmula:C26H33F2N7O3Forma y color:SolidPeso molecular:529.58CHMFL-PI4K-127
CAS:<p>CHMFL-PI4K-127 (15g) selectively inhibits PfPI4K (IC50=0.9 nM), potent against Plasmodium 3D7 (EC50=25.1 nM), with oral anti-malaria activity.</p>Fórmula:C18H15ClN4O3SForma y color:SolidPeso molecular:402.85EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Fórmula:C17H14N4O4S3Forma y color:SolidPeso molecular:434.51EGFR-IN-25
CAS:<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Fórmula:C34H43N9O2Forma y color:SolidPeso molecular:609.76EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Fórmula:C24H25ClN6O3Forma y color:SolidPeso molecular:480.95JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Fórmula:C31H30ClFN4O3SForma y color:SolidPeso molecular:593.11EGFR/HER2-IN-2
CAS:<p>EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual EGFR and HER2 inhibitor that acts on both EGFR (IC50: 5.02 μM) and HER2 (IC50: 0.83 μM).</p>Fórmula:C26H23N5O3Forma y color:SolidPeso molecular:453.49SIC-19
CAS:<p>SIC-19, a SIK2 inhibitor, functions by promoting the degradation of SIK2 protein via the ubiquitination pathway. It inhibits the growth of cancer cells and sensitizes cells, ovarian cancer organoids, and xenograft models to PARP inhibitors (such as Olaparib).</p>Fórmula:C29H26N4O5S2Forma y color:SolidPeso molecular:574.67EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Fórmula:C36H44BrN10O2PForma y color:SolidPeso molecular:759.68PI3Ka-IN-5
CAS:<p>PI3Ka-IN-5 is a potent PI3Kα/mTOR inhibitor, with an IC 50 of 0.7 nM and 3.3 nM, respectively. PI3Ka-IN-5 can be used for the research of colorectal cancer .</p>Fórmula:C30H35N9O5Forma y color:SolidPeso molecular:601.66EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Fórmula:C27H27F3N6O2SForma y color:SolidPeso molecular:556.6ON 146040
CAS:<p>ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.</p>Fórmula:C24H23N7O3SPureza:97.39%Forma y color:SolidPeso molecular:489.55P-2281
CAS:<p>P-2281 is an mTOR inhibitor with anticancer and anti-inflammatory properties.P-2281 inhibits dextran sulfate sodium (DSS)-induced colitis by suppressing T-cell</p>Fórmula:C9H8ClN3OPureza:99.95%Forma y color:SolidPeso molecular:209.63PI3K/mTOR Inhibitor-13
CAS:<p>PI3K/mTOR Inhibitor-13, an oral dual blocker of PI3K and mTOR, may treat sexual diseases, solid tumors, and IPF.</p>Fórmula:C20H13F2N5O3SForma y color:SolidPeso molecular:441.41PI3Kα/mTOR-IN-1
CAS:<p>PI3Kα/mTOR-IN-1 is a potent dual inhibitor of PI3Kα/mTOR.</p>Fórmula:C16H18N6OPureza:99.89%Forma y color:SolidPeso molecular:310.35EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Fórmula:C26H33N9O3SPureza:98.52% - 99.79%Forma y color:SolidPeso molecular:551.66Mutated EGFR-IN-2
CAS:<p>Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.</p>Fórmula:C29H35FN8O3Pureza:98%Forma y color:SolidPeso molecular:562.64PI3K/mTOR Inhibitor-8
CAS:<p>PI3K/mTOR Inhibitor-8: Dual PI3Kα (IC50: 0.46 nM) & mTOR (IC50: 12 nM) inhibitor; blocks G1/S phase & induces apoptosis in HCT-116 cells.</p>Fórmula:C23H22N8O4SForma y color:SolidPeso molecular:506.54PI3K-IN-38
CAS:<p>PI3K-IN-38: oral PI3K inhibitor, IC50 of 0.541 µM, anticancer, anti-inflammatory, halts tumors in vivo.</p>Fórmula:C20H24N6O2Pureza:99.89%Forma y color:SolidPeso molecular:380.44AMPK activator 4
CAS:<p>Potent, selective AMPK activator 4 enhances glucose tolerance and insulin sensitivity without affecting mitochondrial complex I.</p>Fórmula:C24H21ClN2O3Pureza:99.46% - 99.65%Forma y color:SolidPeso molecular:420.89Tyrphostin AG 112
CAS:<p>Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.</p>Fórmula:C13H8N4OPureza:97.01%Forma y color:SolidPeso molecular:236.23PI3K-IN-9
CAS:<p>PI3K-IN-9 is a potent and selective inhibitor of PI3Kδ(IC50 of 8.9 nM).</p>Fórmula:C19H23N7OPureza:98%Forma y color:SolidPeso molecular:365.43EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Fórmula:C14H13N3O2SForma y color:SolidPeso molecular:287.34PI3K-IN-10
CAS:<p>PI3K-IN-10 is a potent inhibitor of pan-PI3K .</p>Fórmula:C23H19ClN6OPureza:98%Forma y color:SolidPeso molecular:430.89PI3Kγ inhibitor 1
CAS:<p>PI3Kγ inhibitor 1 is a inhibitor of PI3Kδ and PI3Kγ.</p>Fórmula:C32H26N8O2SPureza:98%Forma y color:SolidPeso molecular:586.67EGFR/C797S-IN-1
CAS:<p>EGFR/C797S-IN-1: Potent EGFR-C797S inhibitor, IC50 of 0.128 µM, dose-dependent p-EGFR suppression, anti-tumor properties.</p>Fórmula:C28H30N4O3Forma y color:SolidPeso molecular:470.56PI3-Kinase α Inhibitor 2
CAS:<p>Phosphatidylinositol 3-kinase (PI3K) catalyzes the phosphorylation of the 3' hydroxyl position of PIs to produce the second messengers PtdIns-(3,4)-P2 and</p>Fórmula:C16H15N3O2SForma y color:SolidPeso molecular:313.37EGFR-IN-5
CAS:<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Fórmula:C31H38FN9OPureza:98.17%Forma y color:SolidPeso molecular:571.69PI3Kδ/γ-IN-1
CAS:<p>PI3Kδ/γ-IN-1 is a selective and effective inhibitor of PI3Kδ/γ that can be used in the treatment of hematologic malignancies.</p>Fórmula:C25H28N6O4SForma y color:SolidPeso molecular:508.59PP30
CAS:<p>PP30 is an inhibitor of mTORC1 and mTORC2. It is selective within the PI3K family, inhibiting other PI3Ks only at high concentrations.</p>Fórmula:C18H19N7OSPureza:98%Forma y color:SolidPeso molecular:381.45PI3K/mTOR Inhibitor-3
CAS:<p>PI3K/mTOR Inhibitor-3, a potent dual-action anti-cancer imidazoline, targets PI3K and mTOR.</p>Fórmula:C22H23N5OForma y color:SolidPeso molecular:373.45DIF-3
CAS:<p>DIF-3 activates GSK-3β, degrades cyclin D1/c-Myc, and inhibits Wnt/β-catenin in DLD-1 cells, curbing HeLa cell proliferation.</p>Fórmula:C13H17ClO4Pureza:99.57%Forma y color:SolidPeso molecular:272.72EHT 1610
CAS:<p>EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively.</p>Fórmula:C18H14FN5O2SPureza:98.59%Forma y color:SolidPeso molecular:383.4
